{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:58:09Z","timestamp":1787957889283,"version":"build-2784847793"},"reference-count":97,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>This review is focused on the use of hyperimmune globulin therapy to treat some infectious diseases of viral or bacterial origin. Despite the introduction of antibiotics and vaccines, plasma immunoglobulin therapy from whole blood donation can still play a key role. These treatments provide passive transfer of high-titer antibodies that either reduces the risk or the severity of the infection and offer immediate but short-term protection against specific diseases. Antibody preparations derived from immunized human donors are commonly used for the prophylaxis and treatment of rabies, hepatitis A and B viruses, varicella-zoster virus, and pneumonia caused by respiratory syncytial virus, Clostridium tetani, Clostridium botulinum. The use of hyperimmune globulin therapy is a promising challenge, especially for the treatment of emerging viral infections for which there are no specific therapies or licensed vaccines.<\/jats:p>","DOI":"10.3390\/v15071543","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:28:06Z","timestamp":1689294486000},"page":"1543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hyperimmune Globulins for the Management of Infectious Diseases"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-2338","authenticated-orcid":false,"given":"Ilaria","family":"Pati","sequence":"first","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-7367","authenticated-orcid":false,"given":"Mario","family":"Cruciani","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Candura","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Simona","family":"Massari","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Piccinini","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Masiello","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Profili","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"De Fulvio","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Pupella","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Angelis","sequence":"additional","affiliation":[{"name":"National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return to the past: The case for antibody-based therapies in infectious diseases","volume":"21","author":"Casadevall","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1006\/clim.1999.4768","article-title":"Passive antibody therapies: Progress and continuing challenges","volume":"93","author":"Casadevall","year":"1999","journal-title":"Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0887-7963(96)80060-5","article-title":"Appropriate therapeutic use of immunoglobulin","volume":"10","author":"Stiehm","year":"1996","journal-title":"Transfus. Med. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2011.07.005","article-title":"Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases","volume":"25","author":"Hsu","year":"2011","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_6","first-page":"178","article-title":"An old solution for a new problem: Antiserum against emerging infectious diseases","volume":"26","author":"Morais","year":"2016","journal-title":"Front. Public Health"},{"key":"ref_7","unstructured":"Maitta, R.W. (2020). Immunologic Concepts in Transfusion Medicine, Elsevier."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.yapd.2010.08.005","article-title":"Therapeutic use of immunoglobulins","volume":"57","author":"Stiehm","year":"2010","journal-title":"Adv. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tracli.2020.12.005","article-title":"Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand","volume":"28","author":"Brand","year":"2021","journal-title":"Transfus. Clin. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/infdis\/jiy199","article-title":"Anti-Ebola Virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola Virus Disease","volume":"218","author":"Brown","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MOH.0000000000000191","article-title":"The use of convalescent plasma to treat emerging infectious diseases: Focus on Ebola virus disease","volume":"22","author":"Winkler","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.transci.2016.12.014","article-title":"Use of convalescent plasma in Ebola virus infection","volume":"56","author":"Garraud","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1423-0410.1986.tb01952.x","article-title":"Selection of plasma donors suitable for tetanus boosting","volume":"51","author":"Leen","year":"1986","journal-title":"Vox Sang."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/168.3.740","article-title":"Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin","volume":"168","author":"Green","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_16","first-page":"1","article-title":"Preventing tetanus, diphtheria, and pertussis among adults: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel","volume":"55","author":"Kretsinger","year":"2006","journal-title":"MMWR Recomm. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-154-5-201103010-00007","article-title":"Narrative review: Tetanus\u2013a health threat after natural disasters in developing countries","volume":"154","author":"Afshar","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1365-3156.2006.01659.x","article-title":"Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: A meta-analysis","volume":"11","author":"Kabura","year":"2006","journal-title":"Trop. Med. Int. Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MCG.0000000000001330","article-title":"efficacy and safety of monoclonal antibodies against Clostridioides difficile toxins for prevention of recurrent Clostridioides difficile infection: A systematic review and meta-analysis","volume":"55","author":"Akiyama","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa051926","article-title":"Human botulism immune globulin for the treatment of infant botulism","volume":"354","author":"Arnon","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_21","first-page":"CD008123","article-title":"Medical treatment for botulism","volume":"4","author":"Chalk","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_22","first-page":"CD006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"4","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Barten, M.J., Baldanti, F., Status, A., H\u00fcber, C.M., Glynou, K., and Zuckermann, A. (2022). Effectiveness of prophylactic Human Cytomegalovirus Hyperimmunoglobulin in preventing Cytomegalovirus infection following transplantation: A systematic review and meta-analysis. Life, 12.","DOI":"10.3390\/life12030361"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14787210.2021.1846521","article-title":"Hyperimmunoglobulin therapy for the prevention and treatment of congenital cytomegalovirus: A systematic review and meta-analysis","volume":"19","author":"Ghozy","year":"2021","journal-title":"Expert Rev. Anti Infect Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nigro, G., Muselli, M., and On Behalf of the Congenital Cytomegalic Disease Collaborating Group (2023). Prevention of Congenital Cytomegalovirus Infection: Review and Case Series of Valaciclovir versus Hyperimmune Globulin Therapy. Viruses, 15.","DOI":"10.3390\/v15061376"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/14767058.2017.1387890","article-title":"Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: A multicenter study in Madrid","volume":"32","year":"2019","journal-title":"J. Matern.-Fetal Neonatal Med."},{"key":"ref_28","unstructured":"Peter, G. (1997). 1997 Red Book Report of the Committee on Infectious Diseases, American Academy of Pediatrics. [24th ed.]."},{"key":"ref_29","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Fiore","year":"2006","journal-title":"MMWR Recomm. Rep."},{"key":"ref_30","first-page":"CD004181","article-title":"Immunoglobulins for preventing hepatitis A","volume":"2","author":"Liu","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa070546","article-title":"Hepatitis A vaccine versus immune globulin for postexposure prophylaxis","volume":"357","author":"Victor","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0338-4535(83)80122-6","article-title":"Immunoglobulines sp\u00e9cifiques anti-HAV [Anti-HAV-specific immunoglobulins]","volume":"26","author":"Goudemand","year":"1983","journal-title":"Rev. Fr. Transfus. Immunohematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jmv.1890400106","article-title":"Hepatitis A antibody titres after infection and immunization: Implications for passive and active immunization","volume":"40","author":"Zaaijer","year":"1993","journal-title":"J. Med. Virol."},{"key":"ref_34","unstructured":"Centers for Disease Control (1985). Recommendations for protection against viral hepatitis. Morbid. Mortal. Wkly. Rep., 34, 313\u2013335."},{"key":"ref_35","unstructured":"Peter, G. (1997). 1997 Red Book Report of the Committee on Infectious Diseases, American Academy of Pediatrics. [24th ed.]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.3748\/wjg.v21.i42.12083","article-title":"Management of hepatitis B virus infection after liver transplantation","volume":"21","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.34172\/mejdd.2021.197","article-title":"An overview of the current Hepatitis B treatment strategies after liver transplantation","volume":"13","author":"Eslami","year":"2021","journal-title":"Middle East J. Dig. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/CMR.8.1.22","article-title":"Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections","volume":"8","author":"Hemming","year":"1995","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_39","first-page":"CD009417","article-title":"Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection","volume":"8","author":"Sanders","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","first-page":"CD013757","article-title":"Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children","volume":"11","author":"Garegnani","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"The Impact-RSV Study Group (1998). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 102, 531\u2013537.","DOI":"10.1542\/peds.102.3.531"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1474","DOI":"10.1542\/peds.2014-2742","article-title":"Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis","volume":"134","author":"Ralston","year":"2014","journal-title":"Pediatrics"},{"key":"ref_43","unstructured":"Pickering, L.K., Baker, C.J., Kimberlin, D.W., Long, S.S., and American Academy of Pediatrics Committee on Infectious Diseases (2009). Red Book: 2009 Report of the Committee on Infectious Diseases, American Academy of Pediatrics. [28th ed.]."},{"key":"ref_44","unstructured":"UK Health Security Agency (2023, April 14). Guidelines on Post Exposure Prophylaxis (PEP) for Varicella and Shingles (January 2023), Available online: https:\/\/www.gov.uk\/government\/publications\/post-exposure-prophylaxis-for-chickenpox-and-shingles."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1348-0421.2010.00262.x","article-title":"Isolation and characterization of novel human monoclonal antibodies possessing neutralizing ability against rabies virus","volume":"54","author":"Matsumoto","year":"2010","journal-title":"Microbiol. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1016\/j.vaccine.2012.09.027","article-title":"Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: A randomized, dose-escalation phase 1 study in adults","volume":"30","author":"Gogtay","year":"2012","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for postexposure prophylaxis: A phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","unstructured":"(2023, March 09). Italian Medicines Agency\u2014AIFA, Available online: https:\/\/www.aifa.gov.it\/en\/uso-degli-anticorpi-monoclonali."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Toth, D. (2022). Neutralization of SARS-CoV-2 variants by a human polyclonal antibody therapeutic (COVID-HIG, NP-028) with high neutralizing titers to SARS-CoV-2. bioRxiv.","DOI":"10.1101\/2022.01.27.478053"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e03372-20","DOI":"10.1128\/mBio.03372-20","article-title":"The principles of antibody therapy for infectious diseases with relevance for COVID-19","volume":"12","author":"Casadevall","year":"2021","journal-title":"mBio"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Focosi, D., Franchini, M., Tuccori, M., and Cruciani, M. (2022). Efficacy of high-dose polyclonal intravenous immunoglobulin in COVID-19: A systematic review. Vaccines, 10.","DOI":"10.3390\/vaccines10010094"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/imt-2020-0263","article-title":"Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma","volume":"13","author":"Ali","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/imt-2022-0015","article-title":"Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma","volume":"14","author":"Razumikhin","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J.F.-W., Huang, Y., Wang, M., Luo, Y., Yu, J., and Chu, H. (2022). Antibody evasion properties of SARS-CoV-2 omicron sublineages. bioRxiv.","DOI":"10.1101\/2022.02.07.479306"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhou, H., Dcosta, B.M., Landau, N.R., and Tada, T. (2022). Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 variants to vaccine-elicited sera and therapeutic monoclonal antibodies. Viruses, 14.","DOI":"10.3390\/v14061334"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJMp1802256","article-title":"Monoclonal antibodies for emerging infectious diseases\u2014Borrowing from history","volume":"378","author":"Marston","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat. Med."},{"key":"ref_58","unstructured":"European Medicines Agency (2023, April 14). ETF Warns That Monoclonal Antibodies May Not Be Effective against Emerging Strains of SARS-CoV-2, Available online: https:\/\/www.ema.europa.eu\/en\/news\/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2."},{"key":"ref_59","unstructured":"Heggenhougen, H.K. (2008). International Encyclopedia of Public Health, Academic Press."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hart, J., Tillman, G., Kraut, M.A., Chiang, H.-S., Strain, J.F., Li, Y., Agrawal, A.G., Jester, P., Gnann, J.W., and The NIAID Collaborative Antiviral Study Group West Nile Virus 210 Protocol Team (2014). West Nile virus neuroinvasive disease: Neurological manifestations and prospective longitudinal outcomes. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-248"},{"key":"ref_61","unstructured":"Barrett, A.D.T., and Stanberry, L.R. (2009). Vaccines for Biodefense and Emerging and Neglected Diseases, Elsevier. [1st ed.]."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Saiz, J.C. (2020). Animal and Human Vaccines against West Nile Virus. Pathogens, 9.","DOI":"10.3390\/pathogens9121073"},{"key":"ref_63","unstructured":"Italian Ministry of Health (2023, April 14). Piano Nazionale di Prevenzione, Sorveglianza e Risposta alle Arbovirosi (PNA) 2020\u20132025, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2947_allegato.pdf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/AAC.01178-09","article-title":"Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus","volume":"54","author":"Beigel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/00365540500262690","article-title":"Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis","volume":"37","author":"Forrest","year":"2005","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/infdis\/165.4.631","article-title":"Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus","volume":"165","author":"Hoke","year":"1992","journal-title":"J. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1086\/427945","article-title":"Use of interferonalpha in patients with West Nile encephalitis: Report of 2 cases","volume":"40","author":"Kalil","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1086\/596309","article-title":"Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh","volume":"48","author":"Kumar","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1399-0012.2009.01044.x","article-title":"Impact of rituximab-associated Bcell defects on West Nile virus meningoencephalitis in solid organ transplant recipients","volume":"24","author":"Levi","year":"2010","journal-title":"Clin. Transplant."},{"key":"ref_70","first-page":"e13183","article-title":"Management of West Nile Encephalitis: An Uncommon Complication of West Nile Virus","volume":"13","author":"Alli","year":"2021","journal-title":"Cureus"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1086\/377172","article-title":"The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis","volume":"37","author":"Haley","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1034\/j.1399-3062.2002.01014.x","article-title":"Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis","volume":"4","author":"Hamdan","year":"2002","journal-title":"Transpl. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Venturi, G., Fabiani, M., Amendola, A., Marsili, G., Benedetti, E., Fiorentini, C., Fortuna, C., Pupella, S., Pezzotti, P., and Vaglio, S. (2022). Lack of evidence of Chikungunya Virus Infection among blood donors during the Chikungunya outbreak in Lazio Region, Italy, 2017. Viruses, 14.","DOI":"10.3390\/v14030619"},{"key":"ref_74","unstructured":"Pan American Health Organization (2023, April 14). Chikungunya. Available online: https:\/\/www.paho.org\/en\/topics\/chikungunya."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/600381","article-title":"Prophylaxis and therapy for Chikungunya virus infection","volume":"200","author":"Couderc","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3389\/fimmu.2019.01498","article-title":"Immunoglobulin therapy in a patient with severe Chikungunya fever and vesiculobullous lesions","volume":"10","author":"Fernandes","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"105295","DOI":"10.1016\/j.antiviral.2022.105295","article-title":"Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease","volume":"202","author":"Julander","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_78","unstructured":"World Health Organization (2023, April 14). Zika Virus. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/zika-virus."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41541-020-00234-y","article-title":"Passive immunisation of convalescent human anti-Zika plasma protects against challenge with New World Zika virus in cynomolgus macaques","volume":"5","author":"Berry","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"621043","DOI":"10.3389\/fimmu.2020.621043","article-title":"Landscape of monoclonal antibodies targeting Zika and Dengue: Therapeutic solutions and critical insights for vaccine development","volume":"11","author":"Dussupt","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_81","unstructured":"World Health Organization (2023, April 14). Dengue and Severe Dengue. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cellimm.2010.02.005","article-title":"Secondary heterologous dengue infection risk: Disequilibrium between immune regulation and inflammation?","volume":"262","author":"Sierra","year":"2010","journal-title":"Cell. Immunol."},{"key":"ref_83","unstructured":"European Medicines Agency (2023, April 14). New Vaccine to Protect People in the EU and Worldwide against Dengue, Available online: https:\/\/www.ema.europa.eu\/en\/news\/new-vaccine-protect-people-eu-worldwide-against-dengue."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.trstmh.2008.12.011","article-title":"Intravenous immunoglobulins in the treatment of dengue illness","volume":"103","author":"Rajapakse","year":"2009","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.mjafi.2020.12.036","article-title":"Rescue therapy with intravenous immunoglobulin in severe refractory dengue: A pilot study","volume":"78","author":"Padmaprakash","year":"2022","journal-title":"Med. J. Armed Forces India"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Soo, K.M., Khalid, B., Ching, S.M., and Chee, H.Y. (2016). Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154760"},{"key":"ref_87","unstructured":"World Health Organization (2023, April 14). Japanese Encephalitis. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/japanese-encephalitis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s10072-022-05891-6","article-title":"Efficacy and safety of intravenous high-dose immunoglobulin in treatment of the severe form of Japanese encephalitis","volume":"43","author":"Chen","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/jnnp-2011-301993.24","article-title":"1636 Intravenous immunoglobulin to treat Japanese encephalitis; a randomised controlled trial in Nepalese children","volume":"83","author":"Nightingale","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Rayamajhi, A., Nightingale, S., Bhatta, N.K., Singh, R., Kneen, R., Ledger, E., Bista, K.P., Lewthwaite, P., Mahaseth, C., and Turtle, L. (2015). A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS ONE, 10, Erratum in PLoS ONE2015, 10, e0136008.","DOI":"10.1371\/journal.pone.0136008"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.141.10.3606","article-title":"Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies","volume":"141","author":"Yasui","year":"1988","journal-title":"J. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jmv.1890290211","article-title":"Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies","volume":"29","author":"Zhang","year":"1989","journal-title":"J. Med. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e00008-18","DOI":"10.1128\/mBio.00008-18","article-title":"Mouse and human monoclonal antibodies protect against infection by multiple genotypes of Japanese Encephalitis Virus","volume":"9","author":"Fernandez","year":"2018","journal-title":"mBio"},{"key":"ref_94","unstructured":"Italian Medicines Agency, and Italian National Blood Centre (2023, March 09). Guidelines on the Use of Human Immunoglobulins in Case of Shortages, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/847339\/Guidelines_on_the_use_of_human_immunoglobulins_in_case_of_shortages.pdf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV Antibody Combination and Outcomes in Outpatients with COVID-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_97","unstructured":"WHO (2023, June 01). Guideline on the Nonclinical and Clinical Evaluation of Monoclonal Antibodies and Related Biological Products Intended for the Prevention or Treatment of Human Infectious Diseases. WHO\/MAB\/DRAFT\/19 August 2022. English Only. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/call-for-comments\/mab-clinical-guideline---final-for-posting---19aug2022_.pdf?sfvrsn=62728b75_1."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:11:57Z","timestamp":1760127117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":97,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["v15071543"],"URL":"https:\/\/doi.org\/10.3390\/v15071543","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}